A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.

Trial Details

NCT ID
NCT07037758
Phase
PHASE1
Sponsor
Amgen
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Tarlatamab
  • AB248
Locations (sample)
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Los Angeles, California, United States|34.05223,-118.24368
  • Tampa, Florida, United States|27.94752,-82.45843
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Louisville, Kentucky, United States|38.25424,-85.75941

Key Eligibility Criteria

  • Participant has provided informed consent before initiation of any study-specific activities/procedures.
  • Participants ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent.
  • Participants with histologically or cytologically confirmed ES-SCLC that has progressed or recurred following at least 1 line of anti-cancer therap…
  • Participants must have at least 1 measurable lesion as defined by RECIST 1.1 within 21-day screening period, not previously irradiated.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →